Trusted Resources: Education
Scientific literature and patient education texts
Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult With 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity
source: Case reports in neurology
authors: Papaliagkas V,Foroglou N,Toulios P,Moschou M,Gavriilaki M,Notas K,Chatzikyriakou E,Zafeiridou G,Arnaoutoglou M,Kimiskidis VK
summary/abstract:Spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder, typically caused by survival motor neuron 1 (SMN1) gene deletion in chromosome 5q resulting in loss of SMN protein. SMA type 1 progresses rapidly leading to increased mortality usually before the age of 2 years. Nusinersen, the first approved disease-modifying treatment for all 5q-SMA types and ages, is an antisense oligonucleotide administered intrathecally via repeated lumbar punctures. However, adult SMA patients typically present with severe scoliosis and spinal deformity. We present a 28-year-old patient with SMA type 1 and severe spinal deformity, who received nusinersen via a subcutaneously implanted Ommaya reservoir connected with an intrathecal catheter at the thoracic level. The repetitive administrations were completed uneventfully, obviating the need for repeated laborious lumbar punctures and eliminating radiation exposure. In adult SMA patients, performing recurrent lumbar punctures can be technically challenging raising the need for an alternative route of administration. The use of Ommaya reservoirs is a viable, practical for repeated infusions, and safe option for the intrathecal delivery of nusinersen for select cases such as an adult SMA type 1 survivor with severe spinal deformity.
organization: Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, Thessaloniki, Greece.DOI: 10.1159/000519831
read more
Related Content
-
Nusinersen: A Review in 5q Spinal Muscular AtrophySurvival motor neuron 1 (SMN1), located ...
-
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
-
Nonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
Your Guide to Spinal Muscular Atrophyhttps://simedhealth.com/sites/default/fi...
-
Pediatric Spinal Muscular AtrophyWhat is spinal muscular atrophy (SMA)?Sp...
-
H-NMR-Based Metabolic Profiling Identifies Non-Invasive Diagnostic and Predictive Urinary Fingerprints in 5q Spinal ...5q spinal muscular atrophy (SMA) is a di...
-
SMA Type 1 – Looking After Your Child Who Has Had a Recent DiagnosisThe aim of everyone involved in your chi...